The stock may react positively to the secondary endpoint data and upcoming FDA meeting, but the failure to meet the primary endpoint remains a significant regulatory risk. Traders should monitor the FDA feedback in Q2 2026 for clarity on approval potential.
Price Chart
Executive Summary
aTyr Pharma reported full-year 2025 financial results and provided a clinical update, including that its Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis did not meet its primary endpoint, though secondary endpoints showed statistically significant improvements. The company is set to meet with the FDA in April 2026 to determine the path forward for efzofitimod. Cash position was $80.9 million as of year-end.
Key Financial Metrics
Key Facts
- Phase 3 EFZO-FIT™ study did not meet primary endpoint (change in oral corticosteroid dose at week 48).
- Secondary endpoints showed statistical significance for 5.0 mg/kg efzofitimod: KSQ-Lung (p=0.0479), Fatigue Scale (p=0.0226), KSQ-General Health (p=0.0197), and steroid withdrawal with lung improvement (p=0.0196).
- FDA Type C meeting scheduled for mid-April 2026 to review data and determine regulatory path.
- Cash, cash equivalents, and investments totaled $80.9 million as of December 31, 2025.
- Net loss attributable to aTyr was $74.1 million in 2025 vs. $64.0 million in 2024.
Financial Impact
Increased R&D spend to $60.2M in 2025 from $54.4M in 2024; net loss widened to $74.1M from $64.0M. Cash position remains strong at $80.9M, sufficient to support ongoing trials.
Risk Factors
- FDA may not accept secondary endpoints as sufficient for approval despite statistical significance.
- Widening net loss and reliance on future funding or partnerships to sustain operations beyond current cash runway.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250634 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $0.1717 $0.1534 | ▼ −10.66% | ▼ −10.51% | $0.1053 (−38.67%) |
Oct 7, 2026 20d ago | SC 13G/A | $0.2783 $0.1833 | ▼ −34.14% | ▼ −33.16% | $0.1053 (−62.16%) |
Sep 22, 2026 4w ago | Institutional Cluster | $0.3564 $0.3077 | ▲ +13.66% | ▲ +12.48% | $0.1053 (+70.45%) |
Aug 7, 2026 11w ago | 8-K | $0.5289 $0.5189 | ▲ +1.89% | ▲ +1.84% | $0.1053 (+80.09%) |
Jun 11, 2026 19w ago | Institutional Cluster | $0.4754 $0.4629 | ▼ −2.63% | ▼ −3.06% | $0.1053 (−77.85%) |
Jun 8, 2026 20w ago | 8-K | $0.4556 $0.4433 | ▲ +2.70% | ▲ +5.11% | $0.1053 (+76.89%) |
Jun 1, 2026 21w ago | 8-K | $0.5200 $0.4560 | ▼ −12.31% | ▼ −9.34% | $0.1053 (−79.75%) |
May 15, 2026 23w ago | 8-K | $0.5040 $0.4900 | ▼ −2.78% | ▼ −3.74% | $0.1053 (−79.11%) |
May 15, 2026 23w ago | Press Release | $0.5040 $0.4900 | ▼ −2.78% | ▼ −3.74% | $0.1053 (−79.11%) |
May 11, 2026 24w ago | 8-K | $0.5300 $0.5200 | ▼ −1.89% | ▼ −1.96% | $0.1053 (−80.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers